Endocannabinoids Help Mice Adapt to Stress at Hippocampus–Amygdala Synapses
The brain’s own cannabinoid signaling system may help limit the effects of acute stress, according to a 2023 study in mice. Researchers found that endocannabinoids released at connections between the ventral hippocampus and basolateral amygdala helped regulate how animals responded to stressful experiences.
The findings were reported in the Cell Reports study “Endocannabinoid release at ventral hippocampal-amygdala synapses regulates stress-induced behavioral adaptation”. Although the research may point toward future treatment strategies, it does not show that the same mechanism has been demonstrated in humans or that an endocannabinoid-based therapy is ready for clinical use.
Endocannabinoids are signaling molecules produced by the body. They activate cannabinoid receptors, including cannabinoid receptor 1 (CB1), which helps regulate communication between neurons. These compounds are distinct from plant-derived cannabinoids such as THC and CBD, even though they can act on some of the same receptors.
In the study, scientists used a genetically encoded protein sensor to track endocannabinoid release at specific synapses in real time. They found that patterns of activity associated with the amygdala could trigger the release of endocannabinoids at connections carrying signals from the ventral hippocampus, a region involved in memory and emotional processing.
The researchers also detected endocannabinoid release after exposing mice to several types of stress. When they selectively removed CB1 receptors from the hippocampus-to-amygdala pathway, the animals showed less active coping during an acute stress test. They also displayed a reduced preference for sweetened water after stress exposure, a behavioral change the researchers described as consistent with reduced reward seeking.
These results support the idea that endocannabinoid signaling contributes to the brain’s normal adaptation to stress. They also suggest that disrupted signaling in this pathway could influence vulnerability to stress-related symptoms. However, behaviors observed in mice cannot be treated as direct equivalents of depression, post-traumatic stress disorder (PTSD), or other human psychiatric diagnoses.
Stress can contribute to the development or worsening of mental-health conditions, but vulnerability depends on many biological, psychological, and social factors. The National Institute of Mental Health’s overview of PTSD notes that many people experience distress after trauma without developing PTSD, while previous adversity, limited support, and other factors can affect recovery.
The study’s next scientific challenge is determining whether comparable endocannabinoid mechanisms operate in the human brain and whether they can be safely influenced with medication. Potential treatments would need to target specific circuits and signaling processes without causing unwanted effects associated with broad cannabinoid-system activation.
For now, the work provides a clearer picture of how a mouse brain circuit responds to stress. It identifies endocannabinoid release at hippocampus–amygdala synapses as a possible target for future research, not as a proven treatment for stress-related disorders.
